Sánchez-Vizcaíno, F., Tamayo, C., Ramos, F., Láinez-González, D., Serrano-López, J., Barba, R., Martin, M. D., Llamas, P., & Alonso-Dominguez, J. M. (2022). Identification of seasonal variation in the diagnosis of acute myeloid leukaemia: a population-based study. *British Journal of Haematology, 198*(3), 545-555. https://doi.org/10.1111/bjh.18279

Publisher's PDF, also known as Version of record

License (if available): CC BY

Link to published version (if available): 10.1111/bjh.18279

Link to publication record in Explore Bristol Research

PDF-document

This is the final published version of the article (version of record). It first appeared online via Wiley at https://doi.org/10.1111/bjh.18279. Please refer to any applicable terms of use of the publisher.

**University of Bristol - Explore Bristol Research**

**General rights**

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/
INTRODUCTION

Acute myeloid leukaemia (AML) is a rare disease, yet responsible for a large number of cancer-related deaths. The crude incidence rate of AML found in 44 European cancer registries in the years 2000–2002 was 3.6 [95% confidence interval (CI): 3.5–3.7] per 100,000 persons. AML is slightly more frequent among males and is the most common acute leukaemia in infants and adults, with the highest incidence rates being in older people. Mutations that cause AML can occur due to an inherited mutant gene or exposition to certain carcinogens, such as chemotherapy, radiotherapy, ionizing radiation, tobacco and benzene. However, the role of other environmental triggers and biological factors in tumour promotion and/or in proliferation of AML remains unknown.

SUMMARY

Until now, the role that seasonal factors play in the aetiology of acute myeloid leukaemia (AML) has been unclear. Demonstration of seasonality in AML diagnosis would provide supportive evidence of an underlying seasonal aetiology. To investigate the potential seasonal and long-term trends in AML diagnosis in an overall population and in subgroups according to sex and age, we used population-based data from a Spanish hospital discharge registry. We conducted a larger study than any to date of 26,472 cases of AML diagnosed in Spain between 2004 and 2015. Using multivariable Poisson generalized linear autoregressive moving average modelling, we found an upward long-term trend, with monthly incidence rates of AML annually increasing by 0.4% [95% confidence interval (CI), 0.2%–0.6%; p = 0.0011]. January displayed the highest incidence rate of AML, with a minimum average difference of 7% when compared to February (95% CI, 2%–12%; p = 0.0143) and a maximum average difference of 16% compared to November (95% CI, 11%–21%; p < 0.0001) and August (95% CI, 10%–21%; p < 0.0001). Such seasonal effect was consistent among subgroups according to sex and age. Our finding that AML diagnosis is seasonal strongly implies that seasonal factors, such as infectious agents or environmental triggers, influence the development and/or proliferation of disease, pointing to prevention opportunities.

KEYWORDS
acute myeloid leukaemia, diagnosis, infection, leukaemias, seasonality
Demonstration of seasonal variation in the occurrence of AML would, firstly, provide supportive evidence of aetiology by seasonal factors, such as infectious agents or environmental factors; and, secondly, focus research onto the etiological role of such factors. The value of this approach has been recognized previously, although several early studies explored and failed to draw conclusive evidence of the potential seasonality of AML.8–12 A more recent study, however, detected a peak of adult AML diagnoses in the United States during December–January using a large sample of cases between 1992 and 2008.13 Results from this study have since not been confirmed or refuted in other populations.

Due to a lack of consensus on the possible seasonal variation in AML incidence and the progress made within the last decade in data recording and in the development of statistical models for analysing seasonal incidence data,14 further studies examining the possible temporal pattern in the presentation of AML are required. This study utilized population-based data on cases of AML occurring in Spain from a nationwide hospital discharge registry for the years 2004–2015. This is, to our knowledge, the largest study aimed at investigating the potential seasonal and long-term trends in AML incidence in an overall population and in subgroups according to sex and age, while employing novel statistical models with serial dependence for discrete-valued time series.

METHODS

The study was approved by the Ethics Committee for Clinical Research of Hospital Universitario Fundación Jiménez Díaz (EO 100/2017_FJD-HRJC), in accordance with the Declaration of Helsinki. The study was registered on https://clinicaltrials.gov (Identifier: NCT03433521).

Data collection and management

At-risk population

The census of the Spanish general population was obtained from the Spanish National Statistics Institute for the period 2004–2015.15 Data were collected on an annual basis and were stratified by sex in the age groups: 0–4, 5–19, 20–49, 50–64, 65–74, and 75 years and over.

Study population

The Conjunto Mínimo Básico de Datos (CMBD) is a national hospital discharge database that contains anonymized data for approximately 98.0% of public hospital admissions in Spain, and it covers 99.5% of the Spanish population.16,17 Data were obtained from the CMBD on every recorded case of AML. [International Classification of Diseases (ICD)-9 codes: 205.0, acute myeloid leukaemia; 205.3, myeloid sarcoma; 206.0, acute monocytic leukaemia; 207.0, acute erythraemia and erythroleukemia; and 207.2, megakaryocytic leukaemia] in Spain during the period 1997–2015. We extracted information from the register of each case about the date of admission, discharge date, anonymous identifier for each patient, ICD-9 codes, sex and date of birth from which we derived age groups as described for the at-risk population. ICD-9 codes included a second decimal place indicating whether the cancer was active (.00), in remission (.01), or was considered a recurrence (.02). For patients hospitalized on more than one occasion, only the record corresponding to their first diagnosis of AML was selected. To reduce the likelihood of including patients who had been diagnosed with AML before 1997, only patients admitted to hospital and diagnosed with AML in or after 2004 were included in the analysis. Patients whose first recorded diagnosis of AML was classified as remission or recurrence (N = 3471) or that only had the first decimal place of the ICD-9 code recorded (N = 16), were excluded.

Statistical analysis

All analyses were done in R version 3.6.3.18 The date of hospital admission from which the diagnosis of AML was established is the date used for analysis (for simplicity hereafter ‘date of diagnosis’). AML cases per month were standardized to months of equal length. Age/sex-standardized monthly incidence rates of AML were calculated using the census of Spanish population in 2010 as a ‘standard’ population. Age-standardized- and sex-standardized monthly incidence rates of AML were calculated (2010 Spain standard population) and used in stratified analyses performed for sex and age groups respectively. Incidence rates are expressed as the number of AML cases per million person-months at risk if not indicated otherwise.

Nine separate time-series decompositions were performed as an initial exploratory analysis on the monthly incidence rates of AML using data for all cases, and data for each sex and age group. Time series were decomposed into trend, season and remainder components using the STL (Seasonal and Trend decomposition using Loess) method.19 Nine separate Poisson generalized linear autoregressive moving average (GLARMA) models were fitted to evaluate the temporal dynamics in AML incidence using data for all cases, and data for each sex and age group. A detailed description of GLARMA models can be found elsewhere.14 and an enhanced description of the specification of the models used is contained in the Appendix S1. Explanatory variables considered within each model included trend (modelled as a linear trend), monthly seasonality (included as a categorical variable with 12 levels) and December 2015 (dummy variable with two levels). The rate of AML in December 2015 was identified as an outlier from the STL analysis. To account for such an outlier in the data and remove its effect, the variable December 2015 was tested in each model. Multivariable models underwent manual backward step-down selection to
minimize the Akaike information criterion. The selection process of the appropriate lags for the autoregressive (AR) and moving average (MA) components is described in the Appendix S1. The best model was selected based on the likelihood ratio test (LRT) that serial dependence parameters are equal to zero. A version of the Fisher scoring iteration was used to locate a maximum likelihood fit for the model. If overdispersion was detected, then a negative binomial GLARMA model was fitted and retained as the final model if an LRT indicated significantly improved fit. Statistical significance was defined as \( p < 0.05 \).

RESULTS

A total of 26,475 individual patients with a first diagnosis of active AML were hospitalized in Spain and registered at the CMBD during 2004–2015. Information on the sex of the patient was missing for three of the cases, leaving a total of 26,472 patients in the study population. The census of the Spanish population and stratified by sex and age for years 2004–2015 can be found as Table S1.

Descriptive characteristics of sex and age of the patients are shown in Table 1. A greater proportion of cases were male (56.0%) than female. The median age at diagnosis was 67 years (range: 0–103 years; interquartile range: 26 years).

The mean standardized yearly and monthly incidence rates of AML diagnoses over the study period were 47.62 cases per million person-years (standard deviation: 1.01 cases per million person-years) and 3.97 cases per million person-months (standard deviation: 0.43 cases per million person-months) respectively. A higher monthly incidence rate was observed in January in the overall population and in stratified analyses of sex and the age groups 5–19, 20–49, and 50–64 years (Table 2).

Nine time-series plots depicting standardized monthly incidence rates of AML diagnoses for the overall population and stratified by sex and age along with their three components are shown in Figure 1. STL decomposition of the incidence rates observed in the overall population exhibited seasonal fluctuation with a peak in January (Figure 1; Overall population — seasonal panel). A slight upward

| Age (years) | Number (%) of diagnoses by sex | Total (%) |
|-------------|-------------------------------|-----------|
| 0–4         | 189 (1.62)                    | 195 (1.31) | 384 (1.45) |
| 5–19        | 360 (3.09)                    | 464 (3.13) | 824 (3.11) |
| 20–49       | 2355 (20.23)                  | 2645 (17.83) | 5000 (18.89) |
| 50–64       | 2451 (21.06)                  | 3099 (20.90) | 5550 (20.97) |
| 65–74       | 2435 (20.92)                  | 3770 (25.42) | 6205 (23.44) |
| ≥75         | 3851 (33.08)                  | 4658 (31.41) | 8509 (32.14) |
| Total (%)   | 11 641 (43.97)                | 14 831 (56.03) | 26 472 (100) |

| Population | Standardized* (2010 Spanish population) | Mean incidence rate per million person-months | Mean incidence rate per million person-years |
|------------|------------------------------------------|-----------------------------------------------|-----------------------------------------------|
| All Age/sex-standardized incidence rates | 4.45 4.14 3.88 3.99 4.01 3.94 3.77 3.95 3.89 3.89 3.72 3.72 | 47.62 | 47.62 |
| Female Age-standardized incidence rates | 3.61 3.51 3.28 3.37 3.07 3.17 3.14 3.10 3.06 3.17 3.08 2.99 | 38.85 | 38.85 |
| Male Age-standardized incidence rates | 5.53 5.02 4.98 4.74 4.79 4.56 4.61 4.98 4.99 4.99 4.98 4.98 | 59.23 | 59.23 |
| 0–4 years Sex-standardized incidence rates | 1.57 1.01 1.12 0.91 0.60 1.10 1.60 1.44 1.44 1.44 1.37 1.37 | 14.07 | 14.07 |
| 5–19 years Sex-standardized incidence rates | 1.71 1.54 1.99 1.44 1.44 1.00 1.23 1.65 1.65 1.65 1.65 1.65 | 17.94 | 17.94 |
| 20–49 years Sex-standardized incidence rates | 2.01 1.74 1.64 1.71 1.13 1.38 1.54 1.49 1.49 1.49 1.49 1.49 | 25.81 | 25.81 |
| 50–64 years Sex-standardized incidence rates | 2.54 2.44 2.54 2.54 2.54 2.54 2.54 2.54 2.54 2.54 2.54 2.54 | 57.81 | 57.81 |
| ≥75 years Sex-standardized incidence rates | 16.55 16.23 16.04 15.77 15.77 15.77 15.77 15.77 15.77 15.77 15.77 15.77 | 192.09 | 192.09 |

*Acute myeloid leukaemia cases per month were standardized to months of equal length.
IDENTIFICATION OF SEASONALITY IN THE DIAGNOSIS OF AML

A graphical representation of the fitted values from each of the nine final Poisson GLARMA models along with the actual number of cases over time is depicted in Figure 2; it shows that, overall, the models’ fitted values for the response closely trace the observed counts. The lags selected for the autoregressive and moving average components in each model are shown in Table S3. The autocorrelation functions of the Pearson’s residuals indicate that the models have dealt adequately with any serial correlation present (Figure S1).

Summary statistics of the final Poisson GLARMA model for all AML cases are available in Table 3. The final model included an upward linear long-term trend, as well as the variables monthly seasonality and December 2015. The estimated monthly long-term trend implies that the monthly incidence rates of AML diagnoses annually increased by 0.4% (95% CI, 0.2%–0.6%; \( p = 0.0011 \)), given that the other covariates are held constant. January displayed the highest incidence rate of AML, with a minimum average difference of 7% when compared to February (95% CI, 2%–12%; \( p = 0.0143 \)) and a maximum average difference of 16% compared to November (95% CI, 11%–21%; \( p < 0.0001 \)) and August (95% CI, 10%–21%; \( p < 0.0001 \)). The incidence rate of AML for December 2015 was 0.43 (95% CI, 0.34–0.54; \( p < 0.0001 \)) times the average incidence rate for the rest of the study period. Further results from the final Poisson GLARMA models for each sex can be seen in Table 3, and for each age group in Table 4.

**DISCUSSION**

Until now, the role that seasonal factors play in the aetiology of AML has been unclear. The demonstration of seasonality in AML diagnosis would provide supportive evidence of
an underlying seasonal aetiology. This finding would allow further studies to focus on a detailed investigation of specific hypotheses relating to the etiological role of specific seasonal risk factors, such as infectious agents, allergens, or sunlight exposure. Using data from a population-based hospital discharge registry we have carried out a larger study than any to date to investigate whether seasonal variation exists in the diagnosis dates of patients with AML. In addition, we evaluated potential long-term trends in AML incidence and described the standardized incidence rates of AML diagnoses in Spain from 2004 to 2015.

The observed age/sex-standardized monthly incidence rates of AML in Spain over the study period were in line with the age-standardized monthly incidence rates found in a comparable study in the United States. Consistent with previous studies, AML incidence had a male predominance and increased progressively from later adulthood.

This study showed a clear seasonal pattern in the diagnosis of AML, with the highest incidence rates of diagnosis observed in January. These findings are broadly similar to those in a large US-based study by Calip et al. who found a peak of adult AML diagnoses during December–January from 1992 to 2008. Both studies utilize population-based data; however, the U.S. study is restricted to adults aged 25 years and older from a limited number of locations, whilst our study includes data for all ages and from a registry with national coverage. Results from our study (N = 26472 AML cases) and that by Calip et al. (N = 21570) which analysed, respectively, the largest series of AML cases to date in Europe and the United States, provide strong evidence of a monthly variation in AML diagnosis and suggest a seasonal peak in winter months; especially in January, when the peak months found in both studies overlapped.

In contrast, however, earlier studies using cancer registry data from the United States and Europe have failed to find definitive evidence of seasonality in AML diagnosis. There are a number of possible reasons why inconsistent results have occurred. Some previous studies have been based on a small number of cases and lacked statistical power. Further, in early AML studies, where digitized records were non-existent, it is likely that the main results were influenced by a low level of completeness and accuracy. Some of the contrasting results may also be due to the use of different and less advanced statistical approaches, or the failure of some studies to account for serial correlation and/or temporal trends.

In stratified analysis, we observed the presence of seasonal variation in the incidence of AML among females and males with a peak in January. This is broadly consistent with previous studies elsewhere. It is also possible that seasonality is
### TABLE 3  Parameter estimates from the final Poisson GLARMA models fitted for the overall population and each sex

| Parameter         | Overall population | Females | Males |
|-------------------|--------------------|---------|-------|
|                   | Estimates          | SE      | IRR (95% CI) | p     | Estimates | SE | IRR (95% CI) | p | Estimates | SE | IRR (95% CI) | p |
| GLM coefficients  |                    |         |             |     |          |    |             |    |          |    |             |    |
| Intercept         | 1.47               | 0.02    | 4.35 (4.17–4.54) | <0.0001 | 1.25     | 0.03 | 3.49 (3.26–3.74) | <0.0001 | 1.71     | 0.03 | 5.51 (5.23–5.80) | <0.0001 |
| Trend             | 0.0003             | 0.0001  | 1.004a (1.002–1.006)a | 0.0011 | 0.0006   | 0.0002 | 1.007a (1.002–1.012)a | 0.0061 | ...       | ... | ...         | ... |
| December 2015     |                    |         |             |     |          |    |             |    |          |    |             |    |
| No                | ...                | ...     | 1 (ref)     | ... | ...      |    | 1 (ref)     | ... | ...      |    | 1 (ref)     | ... |
| Yes               | −0.84              | 0.11    | 0.43 (0.34–0.54) | −0.78 | 0.17     | 0.46 (0.33–0.64) | −0.91 | 0.15     | 0.40 (0.30–0.54) | <0.0001 |
| Month             |                    |         |             |     |          |    |             |    |          |    |             |    |
| January           | ...                | ...     | 1 (ref)     | ... | ...      |    | 1 (ref)     | ... | ...      |    | 1 (ref)     | ... |
| February          | −0.07              | 0.03    | 0.93 (0.88–0.98) | −0.05 | 0.05     | 0.95 (0.86–1.05) | −10.0 | 0.04     | 0.91 (0.84–0.98) | <0.0001 |
| March             | −0.10              | 0.03    | 0.90 (0.85–0.96) | −0.11 | 0.05     | 0.89 (0.81–0.98) | −10.0 | 0.04     | 0.90 (0.84–0.97) | <0.0001 |
| April             | −0.14              | 0.03    | 0.87 (0.82–0.93) | −0.11 | 0.05     | 0.90 (0.82–0.98) | −15.0 | 0.04     | 0.86 (0.79–0.93) | <0.0001 |
| May               | −0.11              | 0.03    | 0.90 (0.84–0.95) | −0.07 | 0.05     | 0.93 (0.85–1.02) | −14.0 | 0.04     | 0.87 (0.81–0.94) | <0.0001 |
| June              | −0.11              | 0.03    | 0.90 (0.84–0.96) | −0.17 | 0.05     | 0.84 (0.77–0.92) | −10.0 | 0.04     | 0.95 (0.88–1.03) | <0.0001 |
| July              | −0.12              | 0.03    | 0.88 (0.83.94) | −0.13 | 0.05     | 0.87 (0.80–0.96) | −10.0 | 0.04     | 0.90 (0.84–0.97) | <0.0001 |
| August            | −0.17              | 0.03    | 0.84 (0.79–0.90) | −0.14 | 0.05     | 0.87 (0.79–0.95) | −18.0 | 0.04     | 0.84 (0.77–0.91) | <0.0001 |
| September         | −0.12              | 0.03    | 0.89 (0.84–0.94) | −0.14 | 0.05     | 0.87 (0.79–0.95) | −10.0 | 0.04     | 0.91 (0.84–0.98) | <0.0001 |
| October           | −0.11              | 0.03    | 0.89 (0.84–0.95) | −0.13 | 0.05     | 0.88 (0.80–0.96) | −9.0  | 0.04      | 0.91 (0.84–0.99) | <0.0001 |
| November          | −0.18              | 0.03    | 0.84 (0.79–0.89) | −0.16 | 0.05     | 0.85 (0.77–0.93) | −18.0 | 0.04      | 0.84 (0.77–0.90) | <0.0001 |
| December          | −0.13              | 0.03    | 0.88 (0.83–0.93) | −0.14 | 0.05     | 0.87 (0.78–0.96) | −11.0 | 0.04      | 0.90 (0.83–0.97) | <0.0001 |
| ARMA coefficients |                    |         |             |     |          |    |             |    |          |    |             |    |
| Phi               | −0.01              | 0.005   | ...         | 0.0221 | ...      | ... | ...         | ... | −0.02     | 0.01 | ...         | ... |
| Theta             | −0.01              | 0.005   | ...         | 0.0099 | −0.03    | 0.01 | ...         | ... | <0.0040   | −0.02 | 0.01 | ... |

Note: (...) It indicates the reference level of each categorical variable included in the model and each non-significant covariate which was not included in the model. Significant (p < 0.05) results are displayed in bold.

Abbreviations: CI, confidence interval; GLARMA, generalized linear autoregressive moving average; GLM, generalized linear model; SE, standard error.

*a*For the trend, the coefficient estimates are per month, but the incidence rate ratios are annualized for clarity.
more pronounced within particular age groups. Indeed, we found a significant seasonal effect for patients aged 0–4 years, whereas no such effect was detected among patients within the age group of 5–19 years. Interestingly, evidence of seasonal variation was also present in the remaining age groups, except for the oldest group. Elderly patients are frequently diagnosed with AML with myelodysplasia-related changes, whilst younger patients are more commonly diagnosed with AML with recurrent genetic abnormalities. Such variations in the molecular background of AML between the older and younger AML cases may explain the disappearance of seasonal variation in the oldest group.

This study found strong evidence of seasonal variation in the diagnosis of AML, which suggests that seasonal risk factors, such as infectious agents or environmental factors, influence the development and/or proliferation of AML. Our results exhibited a significant annual peak in January. While the underlying reason for this result is unknown, it is possible that the observed peak in monthly AML risk coincides with seasonal elevations in the rates of infectious disease processes which are capable of precipitating or accelerating the course of AML. Indeed, infection has long been suspected as a possible factor in the aetiology of leukaemias. Although no specific agent has yet been identified, parvovirus B19 is suggested to play a role in the aetiology of acute lymphoblastic leukaemia (ALL). Evidence for the involvement of infections in other haematological malignancies is more direct. Notably, a viral aetiology has already been demonstrated in adult T-cell leukaemia/lymphoma related to HTLV-1 infection, and Epstein–Barr virus appears to be aetiologically linked to Hodgkin lymphoma. In addition, several studies conducted in various countries have suggested a seasonal variation in the presentation and diagnosis of ALL and lymphomas which provides further support for an infectious aetiology for these diseases.

While ALL, lymphomas and AML are biologically different diseases and may have distinct aetiologies, there is no reason to think that an infectious component must only be limited to the first two. One reasoning behind such seasonality in AML diagnosis is that a seasonal infectious agent can be capable of promoting leukemogenesis. This explanation requires a short latency period between exposure to this agent and diagnosis of AML which is consistent with the Greaves model. However, cancers known to be associated with infection have been considered as resulting from the prolonged latency that occurs in chronic viral infections. An alternative explanation is that seasonally occurring infectious diseases can stimulate rapid proliferation of pre-existent mutated and quiescent leukaemic stem cells, thereby hastening the diagnosis. This increase in leukaemic stem cell replication could be a consequence of a direct viral insertion in the genome of such cells or the result of an immunological response to an infectious agent.

It is also conceivable that the annual peak observed in January reflects an increased diagnostic activity during winter months; higher levels of healthcare demand because of winter-related illness may lead to the diagnosis of AML. Note, however, that the incidence rates recorded in February and March were higher than the incidence rates observed in December. According to such an explanation, one expects to find higher incidence rates in December if cases that would have otherwise been diagnosed in February and March were being detected in the two months prior because of an increased diagnostic activity. Conversely, some have suggested that observed seasonal variation in certain cancers is likely to reflect the reduced diagnostic activity during vacation months. If such surveillance bias were present in our study, the peak found in January could reflect patients’ delay in seeking medical care or health check-ups until after Christmas holidays. We cannot discard an underestimate of the actual December AML incidence and a corresponding overestimate of the January incidence due to this phenomenon. However, it appears unlikely that the seasonal pattern observed in AML diagnoses can be only explained by lower diagnostic intensity during Christmas holidays, both because of the rapidity and severity of disease onset which will probably lead patients to immediately seek medical care and because of a lack of similar pronounced peaks after other vacation months such as the long summer holidays.

Because the data are from a population-based registry that had a high level of completeness and accuracy throughout the study period, the main results are unlikely to have been influenced by ascertainment or recording bias. However, several potential limitations of this study need to be considered. One limitation is that AML cases were obtained from the CMDB registry as defined by ICD-9 and no other AML classifications were available. Hence, further studies using more modern classifications of AML like the World Health Organization classification would be required to investigate the seasonal variation in the diagnosis of AML subtypes. Another limitation is that information on the date of onset of clinical symptoms was not available for analysis. However, modest variation in the lag period between first symptom and clinical diagnosis would generally be expected because of the rapid progress of the disease. A further limitation relates to the source of our data. Older patients with AML are more likely to be deemed ‘unfit’ or ineligible for intensive chemotherapy and instead they are frequently offered best supportive care or hypomethylating agents for which they often do not require hospitalization. This may have led us to underestimate the incidence rates of AML in older patients as only hospitalized patients were captured in our study. It is also of note that the incidence rate of AML in December 2015 was unusually low. Exploration of this outlier suggested that it can be explained by some patients being hospitalized in December 2015 who were discharged beyond year 2015 and therefore were not captured by our study. Data for each case were only available to us where the discharge date for a patient occurred within the study period from 1997 to 2015. We took account of such an outlier in the data by including December 2015 as an explanatory variable in each of the models.

In conclusion, this large study provides the strongest evidence of a seasonal variation in the diagnosis of AML,
with a significant peak during the month of January. Such seasonal effect was consistent among subgroups according to sex and age. These findings could be used to raise the level of AML suspicion among haematologists where a cytopenia is detected in a complete blood count during winter months, particularly in January. Taken together, previous smaller studies have provided conflicting evidence, likely due to lower power and/or to the use of less advanced statistical approaches. Most studies assessing seasonal trends in AML diagnosis do so in northern-hemisphere countries with temperate climates. Investigation of seasonality in cohorts from a wide range of geographical areas would

| Param       | 0–4 years |                       | 5–19 years |                       | 20–49 years |                       |
|-------------|-----------|------------------------|------------|------------------------|-------------|------------------------|
|             | Est       | SE                     | IRR (95% CI) | p                     | Est         | SE                     | IRR (95% CI) | p         | Est         | SE                     |
| GLM coefficients |          |                        |            |                       |             |                        |            |          |             |                        |
| Intercept   | 0.70      | 0.11                   | 2.02 (1.63–2.51) | <0.0001 | −0.05       | 0.03                   | 0.95 (0.89–1.02) | 0.1703 | 0.69       | 0.05                   |
| Trend       | −0.004     | 0.001                   | 0.96* (0.93–0.98)* | 0.0007 | −0.002      | <0.01                   | 0.98* (0.97–0.99)* | 0.0001 | ...         | ...                   |
| Dec 2015    | ...        | ...                     | ...         | ...                       | ...         | ...                     | ...         | ...         | ...         | ...                   |
| No          | ...        | ...                     | ...         | ...                       | ...         | ...                     | ...         | ...         | ...         | ...                   |
| Yes         | ...        | ...                     | ...         | ...                       | ...         | ...                     | ...         | ...         | ...         | ...                   |
| Month       | ...        | ...                     | 1 (ref)     | ...                       | ...         | ...                     | ...         | ...         | ...         | ...                   |
| Jan         | ...        | ...                     | −0.53 (0.42–0.81) | 0.91 | −0.14       | 0.07                   | ...         | ...         | ...         | ...                   |
| Feb         | −0.28      | 0.15                    | 0.75 (0.56–1.002) | 0.96 | −0.21       | 0.07                   | ...         | ...         | ...         | ...                   |
| Mar         | −0.54      | 0.16                    | 0.58 (0.42–0.80) | 0.98 | −0.16       | 0.07                   | ...         | ...         | ...         | ...                   |
| Apr         | −0.38      | 0.15                    | 0.68 (0.50–0.92) | 0.92 | −0.23       | 0.07                   | ...         | ...         | ...         | ...                   |
| May         | −0.07      | 0.13                    | 0.94 (0.72–1.22) | 0.88 | −0.28       | 0.05                   | ...         | ...         | ...         | ...                   |
| Jun         | −0.19      | 0.14                    | 0.82 (0.62–1.09) | 0.90 | −0.26       | 0.06                   | ...         | ...         | ...         | ...                   |
| Jul         | −0.10      | 0.13                    | 0.90 (0.69–1.17) | 0.96 | −0.19       | 0.07                   | ...         | ...         | ...         | ...                   |
| Aug         | −0.47      | 0.16                    | 0.62 (0.45–0.86) | 0.84 | −0.18       | 0.07                   | ...         | ...         | ...         | ...                   |
| Sep         | −0.30      | 0.15                    | 0.74 (0.55–0.99) | 0.86 | −0.20       | 0.07                   | ...         | ...         | ...         | ...                   |
| Oct         | −0.40      | 0.16                    | 0.67 (0.49–0.91) | 0.88 | −0.19       | 0.07                   | ...         | ...         | ...         | ...                   |
| ARMA coefficients |          |                        |            |                       |             |                        |            |          |             |                        |
| Phi         | ...        | ...                     | ...         | ...                       | −0.08       | 0.03                   | ...         | 0.0145 | 0.06       | 0.02                   |
| Thetaa      | −0.25      | 0.06                    | ...         | <0.0001                  | −0.08       | 0.03                   | ...         | 0.0159 | 0.04       | 0.02                   |
| Thetab      | ...        | ...                     | ...         | ...                       | −0.10       | 0.03                   | ...         | 0.0018 | ...         | ...                   |

Note: (...) indicates the reference level of each categorical variable included in the model and each non-significant covariate which was not included in the model. Significant (p < 0.05) results are displayed in bold.

Abbreviations: CI, confidence interval; Est, estimates; GLARMA, generalized linear autoregressive moving average; GLM, generalized linear model; Param, parameter; SE, Standard error.

aFor the trend, the coefficient estimates are per-month, but the incidence rate ratios are annualized for clarity.

bTheta coefficients for models with only one lag and theta coefficients corresponding to the lowest lag in models with two lags (the selected lags for each model are shown in Table S3).

cTheta coefficients corresponding to the highest lag in models with two lags (the selected lags for each model are shown in Table S3).
|                | 50–64 years |                | 65–74 years |                | ≥75 years |
|----------------|-------------|----------------|-------------|----------------|-----------|
| IRR (95% CI)   | p           | Est            | SE          | IRR (95% CI)   | p         | Est            | SE          | IRR (95% CI)   | p         | Est            | SE          | IRR (95% CI)   | p         |
| 1.98           | <0.0001     | 1.69           | 0.04        | 5.42          | (4.97–5.91)   | 2.51          | 0.04        | 12.3          | (11.3–13.3)   | 2.65          | 0.02        | 14.2          | (13.6–14.9)   | <0.0001       |
|                | <0.0001     |                |             |                |            |                |             |                |              |                |             | <0.0001     |             |
| 1 (ref)        |             |                |             |                | <0.0001    |                |             |                |              |                | <0.0001     |             |
| 0.24           | (0.12–0.49) | −1.66          | 0.36        | 0.19           | (0.09–0.38)  | −0.68          | 0.21        | 0.51           | (0.33–0.77)   | −0.54          | 0.15        | 0.58           | (0.43–0.79)   | <0.0001       |
|                |             | <0.0001        |             |                |             |                |             |                | 0.0006        |                |            |
| 1 (ref)        |             |                |             |                | 0.0193      |                |             |                |              |                |            |
| 0.87           | (0.76–0.99) | −0.09          | 0.06        | 0.91           | (0.80–1.04)  | 0.02           | 0.06        | 1.02           | (0.91–1.15)   |              |             |
| 0.81           | (0.70–0.92) | −0.06          | 0.06        | 0.94           | (0.84–1.06)  | −0.12          | 0.06        | 0.89           | (0.79–1.002)  |              |             |
| 0.85           | (0.74–0.97) | −0.14          | 0.06        | 0.87           | (0.76–0.99)  | −0.19          | 0.07        | 0.83           | (0.73–0.95)   |              |             |
| 0.80           | (0.69–0.91) | −0.04          | 0.06        | 0.96           | (0.85–1.09)  | −0.04          | 0.06        | 0.96           | (0.85–1.08)   |              |             |
| 0.80           | (0.71–0.90) | −0.18          | 0.07        | 0.83           | (0.73–0.95)  | −0.05          | 0.05        | 0.95           | (0.85–1.06)   |              |             |
| 0.75           | (0.68–0.84) | −0.10          | 0.06        | 0.90           | (0.79–1.02)  | −0.12          | 0.06        | 0.88           | (0.78–0.99)   |              |             |
| 0.77           | (0.68–0.87) | −0.23          | 0.07        | 0.80           | (0.70–0.91)  | −0.19          | 0.06        | 0.83           | (0.74–0.92)   |              |             |
| 0.83           | (0.72–0.95) | −0.13          | 0.06        | 0.88           | (0.77–0.99)  | −0.10          | 0.06        | 0.90           | (0.80–1.02)   |              |             |
| 0.84           | (0.73–0.96) | −0.12          | 0.06        | 0.89           | (0.78–1.01)  | −0.10          | 0.07        | 0.90           | (0.79–1.03)   |              |             |
| 0.82           | (0.71–0.94) | −0.20          | 0.06        | 0.82           | (0.73–0.92)  | −0.23          | 0.06        | 0.80           | (0.70–0.90)   |              |             |
| 0.83           | (0.72–0.95) | −0.17          | 0.07        | 0.85           | (0.74–0.96)  | −0.10          | 0.06        | 0.91           | (0.80–1.03)   |              |             |
|                | 0.0017      | 0.03           | 0.01        | 0.0160        |            |                |             |                | −0.02         | 0.009        |            |
|                | 0.0093      |                |             | 0.0167        |            |                |             |                | 0.0114        | 0.02         | 0.01         |            |

It is informative to determine the influence of latitude and climate on AML incidence. The demonstration of seasonality in our study strongly implies that seasonal factors, such as infectious agents or environmental triggers, influence the development and/or proliferation of AML, pointing to prevention opportunities. Analyses were stratified by important person-level covariates such as sex and age that may confound seasonal trends in diagnoses. However, future studies that include more explanatory variables at individual level such as comorbid conditions and environmental exposure would augment the current results, providing further understanding into seasonal variation.
of AML diagnoses and the aetiology behind the observed variation.

AUTHOR CONTRIBUTIONS
The study was conceived and designed by Juan Manuel Alonso-Domínguez and Fernando Sánchez-Vizcaíno. The funding for the project leading to this publication was acquired by Juan Manuel Alonso-Domínguez and Fernando Sánchez-Vizcaíno. The data were acquired by Raquel Barba, María Dolores Martin and Juan Manuel Alonso-Domínguez. The data curation was carried out by Fernando Sánchez-Vizcaíno and Carmen Tamayo. The methodology, formal analysis and visualization were conducted by Fernando Sánchez-Vizcaíno. The manuscript was drafted by Fernando Sánchez-Vizcaíno and Juan Manuel Alonso-Domínguez. The manuscript was revised critically for important intellectual content by Carmen Tamayo, Fernando Ramos, Daniel Láinez-González, Juana Serrano-López, Raquel Barba, María Dolores Martin and Pilar Llamas. All authors gave final approval for publication.

ACKNOWLEDGEMENTS
This study was supported by research funding from Celgene S.L. to Juan Manuel Alonso-Domínguez and Fernando Sánchez-Vizcaíno. We wish to thank the staff of the Conjunto Mínimo Básico de Datos (CMBD), for providing us with the data for analysis. Open Access funding enabled and organized by Projekt DEAL.

FUNDING INFORMATION
This study was supported by research funding from Celgene S.L.

CONFLICT OF INTERESTS
Juan Manuel Alonso-Domínguez received research funding from Incyte Corporation, Pfizer International, and Astellas Pharma Inc. outside the present work.

DATA AVAILABILITY STATEMENT
Publicly available data were obtained from the Spanish National Statistics Institute. All other data and codes are available upon request from the authors after appropriate approvals.

ORCID
Fernando Sánchez-Vizcaíno https://orcid.org/0000-0002-1655-8290
Fernando Ramos https://orcid.org/0000-0002-4991-2655
Daniel Láinez-González https://orcid.org/0000-0002-2726-1193
Juan Manuel Alonso-Domínguez https://orcid.org/0000-0001-6233-5912

REFERENCES
1. Deschler B, Lübbert M. Acute myeloid leukemia: epidemiology and etiology. Cancer. 2006;107:2099–107.
2. Sant M, Allemani C, Tereanu C, de Angelis R, Capocaccia R, Visser O, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010;116:3724–34.
3. University of Chicago Hematopoietic Malignancies Cancer Risk Team. How I diagnose and manage individuals at risk for inherited myeloid malignancies. Blood. 2016;128:1800–13.
4. Rinsky RA, Hornung RW, Landrigan PJ. Re: ‘Benzene and Leukemia: a Review of the Literature and a Risk Assessment’. Am J Epidemiol. 1989;129:1084–6.
5. Levine EG, Bloomfield CD. Leukemias and myelodysplastic syndromes secondary to drug, radiation, and environmental exposure. Semin Oncol. 1992;19:47–84.
6. Sandler DP, Shore DL, Anderson JR, Davey FR, Arthur D, Mayer RJ, et al. Cigarette smoking and risk of acute leukemia: associations with morphologic and cytogenetic abnormalities in bone marrow. J Natl Cancer Inst. 1993;85:1994–2003.
7. Papamannui E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374:2209–21.
8. Lee JAH. Seasonal variation in leukaemia incidence. Br Med J. 1963;2:623.
9. Douglas S, Cortina-Borja M, Cartwright R. A quest for seasonality in presentation of leukaemia and non-Hodgkin's lymphoma. Leuk Lymphoma. 1999;32:523–32.
10. Timonen TT. A hypothesis concerning deficiency of sunlight, cold temperature, and influenza epidemics associated with the onset of acute lymphoblastic leukemia in northern Finland. Ann Hematol. 1999;78:408–14.
11. Walker AM, van Noord PA. No seasonality in the diagnosis of acute leukemia in the United States. J Natl Cancer Inst. 1982;69:1283–7.
12. Ross JA, Severson RK, Pollock BH, Gurney JG, Robison LL. Seasonal variations in the diagnosis of childhood cancer in the United States. Br J Cancer. 1999;81:549–53.
13. Calip GS, McDougall JA, Wheldon MC, Li CJ, De Roos AJ. Evaluation of seasonality in the diagnosis of acute myeloid leukaemia among adults in the United States, 1992-2008. Br J Haematol. 2013;160:343–50.
14. Dunsmuir WTM, Scott DJ. The glarma package for observation-driven time series regression of counts. J Stat Softw. 2015;67:1–36.
15. Instituto Nacional de Estadística. Instituto Nacional de Estadística. Estadística del Padrón continuo. Resultados. https://www.ine.es/dyngs/INEbase/es/operacion.htm?origEstadistica_C&cid=1254736177012&menu=resultados&idp=125473410990#tabs-1254736195461. Accessed 25 November 2020.
16. Ministerio de Sanidad, Consumo y Bienestar Social. Statiscal Site of the NHS - Hospital Discharge Records in the National Health System CMBD. https://www.mscbs.gob.es/en/estadEstudios/estadisticas/cmbdhome.htm. Accessed 06 November 2020.
17. Ministerio de Sanidad, Consumo y Bienestar Social. Ministerio de Sanidad, Consumo y Bienestar Social. https://www.mscbs.gob.es/estadEstudios/estadisticas/docs/analis.pdf. Accessed 25 November 2020.
18. R Core Team (2020). R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing. https://www.R-project.org/. Accessed 29 February 2020.
19. Cleveland RB, Cleveland WS, McRae JE, Terpenning I. STL: a seasonal-trend decomposition procedure based on loess. J Off Stat. 1990;6(1):3–73.
20. Shalvis RM, Weiss JJ, Deziel NC, Gore SD. Challenging the concept of de novo acute myeloid leukemia: environmental and occupational leukemogens hiding in our midst. Blood Rev. 2020;47:100760.
21. Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg CL, et al. SEER Cancer Statistics Review, 1975-2000. National Cancer Institute. Bethesda, MD. https://seer.cancer.gov/csr/1975_2000/. Accessed 01 December 2020. https://seer.cancer.gov/archive/csr/1975_2000/index.html (accessed Jan 4, 2021).
22. Forman D, Stockton D, Moller H, Quinn M, Babb P, de Angelis R, et al. Cancer prevalence in the UK: results from the EUROPREVAL study. Ann Oncol Off J Eur Soc Med Oncol. 2003;14:648–54.
23. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid
Tissues. 4th ed. Lyon: International Agency for Research in Cancer; 2017.
24. Greaves MF, Alexander FE. An infectious aetiology for common acute lymphoblastic leukaemia in childhood? Leukemia. 1993;7:349–60.
25. Kinlen LJ. Epidemiological evidence for an infective basis in childhood leukaemia. Br J Cancer. 1995;71:1–5.
26. Kerr JR, Mattey DL. The role of parvovirus B19 and the immune response in the pathogenesis of acute leukemia. Rev Med Virol. 2015;25:133–55.
27. Flavell KJ, Murray PG. Hodgkin’s disease and the Epstein-Barr virus. Mol Pathol. 2000;53:262–9.
28. Harris RE, Harrell FE, Patil KD, Al-Rashid R. The seasonal risk of pediatric/juvenile acute lymphocytic leukemia in the United States. J Chronic Dis. 1987;40:915–23.
29. Badrinath P, Day NE, Stockton D. Seasonality in the diagnosis of acute lymphocytic leukaemia. Br J Cancer. 1997;75:1711–3.
30. Westerbeek RM, Blair V, Eden OB, Kelsey AM, Stevens RF, Will AM, et al. Seasonal variations in the onset of childhood leukaemia and lymphoma. Br J Cancer. 1998;78:119–24.
31. Shim KS, Kim MH, Shim CN, Han M, Lim IS, Chae SA, et al. Seasonal trends of diagnosis of childhood malignant diseases and viral prevalence in South Korea. Cancer Epidemiol. 2017;51:118–24.
32. Greaves M. Infection, immune responses and the aetiology of childhood leukaemia. Nat Rev Cancer. 2006;6:193–203.
33. Haeri M, Li Y, Li Y, Li Q, Spaner DE, Ben-David Y. Insertional activation of myb by F-MuLV in SCID mice induces myeloid leukemia. Int J Oncol. 2013;43:169–76.
34. Li Z, Ma R, Ma S, Tian L, Lu T, Zhang J, et al. ILC1s control leukemia stem cell fate and limit development of AML. Nat Immunol. 2022;23:718–30. https://doi.org/10.1038/s41590-022-01198-y
35. Lambe M, Blomqvist P, Bellocco R. Seasonal variation in the diagnosis of cancer: a study based on national cancer registration in Sweden. Br J Cancer. 2003;88:1358–60.
36. Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424–47.

SUPPORTING INFORMATION
Additional supporting information may be found in the online version of the article at the publisher’s website.

How to cite this article: Sánchez-Vizcaíno F, Tamayo C, Ramos F, Láinez-González D, Serrano-López J, Barba R, et al. Identification of seasonal variation in the diagnosis of acute myeloid leukaemia: a population-based study. Br J Haematol. 2022;198:545–555. https://doi.org/10.1111/bjh.18279